ASK REDCHAT ANYTHING ABOUT BIOLINERX LTD.
BioLineRx Ltd. (NASDAQ: BLRX)
Listen to this Section
$3.29
-0.0700
(
-2.08% )
4.5K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| APHEXDA®(Motixafortide )(BL-8040) (CXCR4 antagonist)DetailsStem cell mobilization, Multiple myeloma |
Approved |
| Motixafortide (BL-8040) w/ zimberelimabDetailsPancreatic cancer, Cancer, Solid tumor/s |
Phase 2b |
| Motixafortide (BL-8040) w/ cemiplimabDetailsCancer, Solid tumor/s, Pancreatic cancer |
Phase 2 |
| Motixafortide (BL-8040)DetailsBlood disorder, Sickle cell disease |
Phase 1 |
| Motixafortide (BL-8040) +/- natalizumabDetailsSickle cell disease, Blood disorder |
Phase 1 |
| AGI-134DetailsSolid tumor/s, Cancer |
Failed |
| Motixafortide (BL-8040) (CXCR4 antagonist)DetailsAcute myeloid leukemia |
Failed |
| Motixafortide (BL-8040) (CXCR4 antagonist)DetailsPancreatic cancer, Solid tumor/s, Cancer |
Failed |
Market Data
|
| Open |
$3.29 |
| Previous Close |
$3.36 |
| Volume |
4.5K |
| Market Cap |
$14.27M |
| Day Range |
$3.20 - $3.58 |
| 52 Week Range |
$2.15 - $6.59 |
| Shares Outstanding |
4.35M |
| Change % |
-2.08% |
| Net Change |
▼ -0.0700 |
| Insider Ownership |
N/A |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2011 |
| Country | Israel |
Insider Ownership Transactions
Total Amount Purchased:
0.00
| Date |
Type |
Amount Purchased |
Purchaser |
| No records found. |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 3 |
Insider transactions |
1 |
Mar 18, 2026 |
| 6-k |
Form 6-K |
2 |
Feb 23, 2026 |
| s-8 |
Registration statements |
19 |
Jan 23, 2026 |
| 6-k |
Form 6-K |
6 |
Nov 24, 2025 |
| 6-k |
Form 6-K |
3 |
Nov 17, 2025 |
| 6-k |
Form 6-K |
6 |
Sep 29, 2025 |
| 6-k |
Form 6-K |
45 |
Aug 14, 2025 |
| schedule |
Other |
1 |
Aug 14, 2025 |
| 424b5 |
Other |
2 |
Jul 25, 2025 |
| 6-k |
Form 6-K |
1 |
Jun 30, 2025 |